Third time lucky? India sends Sutent case back for fresh review
This article was originally published in Scrip
Two patent revocations later, Pfizer has received a significant reprieve with India's Intellectual Property Appellate Board (IPAB) sending the case concerning its anticancer, Sutent (sunitinib malate), back to the Controller General of Patents to review the matter afresh.
You may also be interested in...
Pfizer is pushing ahead with legal action in India to ward off an alleged infringer of its patent on Sutent - a product that has had a checkered patent journey in the country.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.